Literature DB >> 34546787

Sex Differences in Patients With Suspected Cardiac Sarcoidosis Assessed by Cardiovascular Magnetic Resonance Imaging.

Rajat Kalra1, Shray Malik1, Ko-Hsuan Amy Chen1, Fredrick Ogugua1, Pal Satyajit Singh Athwal1, Andrew C Elton1, Pratik S Velangi1, Mohamed F Ismail1, Sanya Chhikara1, Jeremy S Markowitz1, Prabhjot S Nijjar1, Lisa von Wald1, Henri Roukoz1, Maneesh Bhargava2, David Perlman2, Chetan Shenoy1.   

Abstract

Background: There are few data on sex differences in suspected cardiac sarcoidosis.
Methods: Consecutive patients with histologically proven sarcoidosis and suspected cardiac involvement were studied. We investigated sex differences in presenting features, cardiac involvement, and the long-term incidence of a primary composite end point of all-cause death or significant ventricular arrhythmia and secondary end points of all-cause death and significant ventricular arrhythmia.
Results: Among 324 patients, 163 (50.3%) were female and 161 (49.7%) were male patients. Female patients had a greater prevalence of chest pain (37.4% versus 23.6%; P=0.010) and palpitations (39.3% versus 26.1%; P=0.016) than male patients but not dyspnea, presyncope, syncope, or arrhythmias at presentation. Female patients had a lower prevalence of late gadolinium enhancement on cardiovascular magnetic resonance imaging (20.2% versus 35.4%; P=0.003) and less often met criteria for a clinical diagnosis of cardiac sarcoidosis (Heart Rhythm Society consensus criteria, 22.7% versus 36.0%; P=0.012 and 2016 Japanese Circulation Society guideline criteria, 8.0% versus 19.3%; P=0.005), indicating lesser cardiac involvement. However, the long-term incidence of all-cause death or significant ventricular arrhythmia was not different between female and male patients (23.2% versus 23.2%; P=0.46). Among the secondary end points, the incidence of all-cause death was not different between female and male patients (20.7% versus 14.3%; P=0.51), while female patients had a lower incidence of significant ventricular arrhythmia compared with male patients (4.3% versus 13.0%; P=0.022). On multivariable analyses, sex was not associated with the primary end point (hazard ratio for female patients, 1.36 [95% CI, 0.77–2.43]; P=0.29). Conclusions: We observed distinct sex differences in patients with suspected cardiac sarcoidosis. A paradox was identified wherein female patients had a greater prevalence of chest pain and palpitations than male patients, but lesser cardiac involvement, and a similar long-term incidence of all-cause death or significant ventricular arrhythmia.

Entities:  

Keywords:  arrhythmias, cardiac; cardiomyopathies; magnetic resonance imaging; prevalence; prognosis; sarcoidosis; sex characteristics

Mesh:

Year:  2021        PMID: 34546787      PMCID: PMC8462066          DOI: 10.1161/CIRCEP.121.009966

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  32 in total

1.  Global Coronary Flow Reserve Measured During Stress Cardiac Magnetic Resonance Imaging Is an Independent Predictor of Adverse Cardiovascular Events.

Authors:  Raksha Indorkar; Raymond Y Kwong; Simone Romano; Brent E White; Richard C Chia; Michael Trybula; Kaleigh Evans; Chetan Shenoy; Afshin Farzaneh-Far
Journal:  JACC Cardiovasc Imaging       Date:  2018-11-05

Review 2.  Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.

Authors:  B A Rybicki; M Major; J Popovich; M J Maliarik; M C Iannuzzi
Journal:  Am J Epidemiol       Date:  1997-02-01       Impact factor: 4.897

3.  Clinical characteristics of patients in a case control study of sarcoidosis.

Authors:  R P Baughman; A S Teirstein; M A Judson; M D Rossman; H Yeager; E A Bresnitz; L DePalo; G Hunninghake; M C Iannuzzi; C J Johns; G McLennan; D R Moller; L S Newman; D L Rabin; C Rose; B Rybicki; S E Weinberger; M L Terrin; G L Knatterud; R Cherniak
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

Review 4.  Sex differences in pain: a brief review of clinical and experimental findings.

Authors:  E J Bartley; R B Fillingim
Journal:  Br J Anaesth       Date:  2013-07       Impact factor: 9.166

5.  18F-FDG-PET in Finnish patients with clinical suspicion of cardiac sarcoidosis: Female sex and history of atrioventricular block increase the prevalence of positive PET findings.

Authors:  Heikki Tuominen; Atte Haarala; Antti Tikkakoski; Pasi Korkola; Mika Kähönen; Kjell Nikus; Kalle Sipilä
Journal:  J Nucl Cardiol       Date:  2017-06-05       Impact factor: 5.952

6.  Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption.

Authors:  J De Vries; G L Van Heck; M Drent
Journal:  Women Health       Date:  1999

Review 7.  Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis.

Authors:  G Cameron Coleman; Peter W Shaw; Pelbreton C Balfour; Jorge A Gonzalez; Christopher M Kramer; Amit R Patel; Michael Salerno
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-20

8.  The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States.

Authors:  M A Judson; A D Boan; D T Lackland
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2012-10       Impact factor: 0.670

9.  Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data.

Authors:  N M Gideon; D M Mannino
Journal:  Am J Med       Date:  1996-04       Impact factor: 4.965

10.  Cardiac Sarcoidosis: Is it More Common in Men?

Authors:  Magdalena M Martusewicz-Boros; Piotr W Boros; Elżbieta Wiatr; Anna Kempisty; Dorota Piotrowska-Kownacka; Kazimierz Roszkowski-Śliż
Journal:  Lung       Date:  2015-09-28       Impact factor: 2.584

View more
  1 in total

1.  Arrhythmia Monitoring and Outcomes in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium.

Authors:  Edoardo Bressi; Thomas C Crawford; Frank M Bogun; Xiaokui Gu; Kenneth A Ellenbogen; Alexandra B Chicos; Henri Roukoz; Peter J Zimetbaum; Steven J Kalbfleisch; Francis D Murgatroyd; David A Steckman; Lynda E Rosenfeld; Ann C Garlitski; Kyoko Soejima; Adarsh K Bhan; Vasanth Vedantham; Timm M Dickfeld; David B De Lurgio; Pyotr G Platonov; Matthew M Zipse; Suguru Nishiuchi; Matthew L Ortman; Calambur Narasimhan; Kris K Patton; David G Rosenthal; Siddharth S Mukerji; Jarieke C Hoogendoorn; Katja Zeppenfeld; William H Sauer; Jordana Kron
Journal:  J Am Heart Assoc       Date:  2022-06-22       Impact factor: 6.106

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.